关于我们
Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Our vision is to deliver pivotal information to physicians early in pregnancy to help them to improve the health of their patients and reduce costs of healthcare delivery. The PreTRM? Test reports to a physician the individualized risk of premature birth, enabling earlier proactive interventions in patients with higher risk. We're also developing a robust pipeline of innovative tests focused on other complications of pregnancy, including preeclampsia, gestational diabetes, growth restriction, and others. Learn more about our values, culture, and open positions on our website.
- 网站
-
https://seraprognostics.com/
Sera Prognostics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Salt Lake City，UT
- 类型
- 私人持股
- 创立
- 2008
- 领域
- Maternal Fetal Medicine、Proteomics、Preterm Birth、Prematurity、Obstetrics、Pregnancy、preemie和premature birth
地点
Sera Prognostics员工
-
Michael Penn
Investor, Board Member, Startup Advisor, Healthcare and Biotech STEM Diversity/Innovation Expert, Author, Speaker
-
Robert G. Harrison
Chief Information Officer at Sera Prognostics, Inc.
-
Paul Kearney
Chief Data Officer @ Sera Prognostics | Machine Learning/AI Leader | Bioinformatics | Biostatistics | Personalized Medicine | Data Innovation
-
Ben Jackson
General Counsel at Sera Prognostics | CORPORATE GOVERNANCE, INTELLECTUAL PROPERTY, REGULATORY COMPLIANCE, CONTRACTS, SUPPLY CHAIN, HUMAN RESOURCES,…
动态
-
One of the Largest Studies on Preterm Birth Finds a Maternal Biomarker Test Significantly Reduces Neonatal Morbidities and Improves Neonatal Outcomes In the preterm birth prevention group that was screened and treated if the mother had a higher risk test result, data showed a 20 percent reduction in neonatal morbidity and a 20 percent reduction in NICU admissions. Results also further demonstrated that infants who were admitted to the NICU had a 6-8 percent reduction in the length of stay.
-
“This study is the first to combine a biomarker test that screened a large segment of the population who do not have the typical risk factors for preterm birth with a targeted treatment plan for those who were identified to be at higher risk and demonstrated dramatic improvements in neonatal outcomes,” says the study’s lead author Brian Iriye, MD
-
“We need to change the mindsets of researchers, investors and entrepreneurs in the maternal care space to start bringing more and more innovations to maternal care to reverse this terrible trend of maternal mortality.” - Zhenya Lindgart, President and CEO of Sera Prognostics
Ep. 311: Breakthroughs in Preterm Birth Prevention with Zhenya Lindgardt | The Birth Lounge Podcast
podcast.thebirthlounge.com
-
“Women’s health – especially maternal and neonatal health – continues to demand greater public attention and healthcare intervention. In the context of staffing shortages and healthcare deserts in the US, I see 2025 being a year of further innovation to drive improvements in care. Consumer-centered women’s health solutions – like diagnostics - will continue to play?a significant role in improving women’s health outcomes. With new tools and resources available for physicians and women, I’m excited to see what transformations this year will bring!” - Zhenya Lindgardt, CEO and president, Sera Prognostics
-
"In healthcare innovation, few areas have grown as rapidly or impacted as profoundly as Femtech. With a focus on the unique needs of women, this dynamic field continues to pioneer solutions that improve outcomes, reduce disparities, and empower women to take charge of their health."
-
"BlackDoctor.org spoke with Dr. Barbi Phelps-Sandall, a board-certified OB/GYN who runs a practice in Mountain View, California, to discuss how the PreTRM? Test works, why it’s especially important for Black women, and what you can do to protect yourself and your baby during pregnancy."